Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Jan
21
Today In Oncology
IMPT vs IMRT in Oropharyngeal Cancer
Investigational Vaccine Intercepts Cancer Cells in Lynch Syndrome Carriers
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer
Axillary Recurrence With or Without ALND in Patients With Residual Micrometastases After Neoadjuvant Chemotherapy for Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo